GlycoMimetics to Present New Preclinical Data Highlighting Biomarkers and Potential Expanded Pipeline Opportunities at Virtual AACR Annual Meeting 2020
During the June session,
Important findings from the preclinical research include:
- Co-targeting and inhibition of E-selectin/CXCR4/FLT3 with GMI-1359 in combination with sorafenib exerts protection of normal hematopoiesis (blood cell formation) and more efficiently reduces leukemic burden compared to sorafenib alone, resulting in extended overall survival, in a patient-derived FLT3 resistant AML model;
- Inhibition of E-selectin with uproleselan during pre-transplant conditioning results in increased survival of mice in a hematopoietic stem cell transplantation and reconstitution model; and,
- Further analysis of E-selectin glycosylation genes extends the prognostic importance of this unique gene signature in AML, highlighting the potential use of uproleselan in AML and other hematologic malignancies.
“We look forward to presenting data at this year’s AACR meeting that will support our approach to targeting E-selectin with both uproleselan and GMI-1359 as part of potential treatment regimens for patients with AML and other diseases,” said
Of note, data will be presented demonstrating that lethality of the FLT-3 mutation is specifically dependent upon high levels of E-selectin ligand expressed on the surface of AML blasts. FLT-3 ITD AML patients are known to express higher levels of E-selectin on the vasculature endothelium. In the patient data to be reported at the AACR meeting, patients who had the FLT-3 ITD mutation, but presented low levels of E-selectin ligand on their AML cells, did not experience worse outcomes, whereas those who did have FLT-3 ITD with high levels of E-selectin ligand, experienced poor survival. This adds support to the key role of E-selectin ligand in contributing to poor outcomes in AML and to the potential of uproleselan to improve AML treatment.
Details on
- Abstract Control #7924/ Permanent Abstract #5867:
“Transcriptome profiling of ST3GAL4 and FUT7 in multiple tumor types and prognostic value in adult acute myeloid leukemia”
Session Type: Poster Session
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Functional Genomics and Other Topics
- Abstract Control #3865/ Permanent Abstract #486:
“Enhanced survival of lethally-irradiated mice with HSC reconstitution in combination with the E-selectin antagonist, GMI-1271 (uproleselan)”
Session Type: Poster Session
Session Category: Tumor Biology
Session Title: Stem Cells, Cancer Stem Cell Therapeutic Targeting, and Regenerative Medicine
- Abstract #5038:
“Combined Targeting of E-selectin/CXCR4 and FLT3 by GMI-1359 and Sorafenib Effectively Reduces Leukemia Cell Burden and Protects Normal Hematopoiesis in a Patient-derived AML Xenograft Model”
Session Type: Poster Session
Session Category: Tumor Biology
Session Title: Drug Targets in the Microenvironment
Meeting abstracts are available at AACR's website.
About Uproleselan
Discovered and developed by
About GMI-1359
GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4. E-selectin and CXCR4 are both adhesion molecules involved in tumor trafficking and metastatic spread. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow such as AML and multiple myeloma or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer, as well as in osteosarcoma, a rare pediatric tumor. GMI-1359 has completed a Phase 1 clinical trial in healthy volunteers. The Duke University Phase 1b clinical study in breast cancer patients is designed to enable investigators to identify an effective dose of the drug candidate and to generate initial biomarker data around the drug’s activity. GMI-1359 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for the treatment of osteosarcoma, a rare cancer affecting about 900 adolescents a year in
About
Forward-Looking Statements
This press release contains forward-looking statements regarding the clinical development and potential benefits and impact of the Company’s drug candidates. These forward-looking statements include those relating to the planned clinical development of the Company’s wholly-owned product candidates. Actual results may differ materially from those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20200515005324/en/
Investor:
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media:
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
Source: